Article info

Download PDFPDF

Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial

Authors

  1. Correspondence to Dr Yongjun Wang; yongjunwang{at}ncrcnd.org.cn
View Full Text

Citation

Xiong Y, Campbell BCV, Fisher M, et al
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial

Publication history

  • Received January 16, 2023
  • Accepted May 1, 2023
  • First published May 29, 2023.
Online issue publication 
February 27, 2024

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.